| Date | Title | Description | |
|---|---|---|---|
| 12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 02 Feb 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 26 January and 1 February 2024 | Download |
| 26 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 19 January and 25 January 2024 | Download |
| 19 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 12 January and 18 January 2024 | Download |
| 12 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 5 January and 11 January 2024 | Download |
| 05 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 29 December 2023 and 4 January 2024 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 07 Nov 2019 | Information on P&L | ROVI releases the first nine months 2019 results presentation | Download |
| 03 Oct 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the third quarter of 2019 | Download |
| 05 Sep 2019 | Others on business performance and financial information | The Company informs about the construction of a second heparin plant in Granada | Download |
| 30 Jul 2019 | Information on P&L | ROVI releases the first half 2019 results presentation | Download |
| 30 Jul 2019 | Information on P&L | ROVI releases the press release related to the first half 2019 financial results | Download |